CytoSorbents Launches VetResQ™ for U.S. Veterinary Market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
CytoSorbents (CTSO) PT Raised to $10 at Maxim Group
January 23, 2017 12:19 PM ESTMaxim Group analyst Gabrielle Zhou raised her price target Buy-rated CytoSorbents (NASDAQ: CTSO) to $10.00 (from $8.00) as VetResQ launches into the U.S. vet market.
Zhuo highlighted:
CytoSorbents announced the launch of the VetResQ sorbent cartridge for the U.S. veterinary market. VetResQ was showcased at the American College of Veterinary Emergency and Critical Care (ACVECC) Post-graduate Review Course from Jan. 20-21 in Honolulu, Hawaii.Similar to CytoSorb, VetResQ is a broad spectrum blood... More